Latamoxef can induce severe coagulopathy in older patients, particularly those with risk factors such as vitamin-K deficiency, renal dysfunction, or concurrent anticoagulant therapy.
Answers are grounded in this paper and cite their sources.
May warrant coagulation monitoring in elderly latamoxef recipients with vitamin K deficiency; hypothesis-generating case report requiring confirmation.
We report on two cases of coagulopathy in patients given latamoxef. Advanced age, deficiency in vitamin-K intake, poor nutritional status, abnormal coagulation history, ongoing anti-coagulation/anti-aggregation therapy, renal dysfunction and polypharmacy are possible contributory factors, and should be looked out for when prescribing latamoxef.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: